Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Multicenter, Open Label, Dosefinding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual Dna-pk and Tor Kinase Inhibitor, Cc-115, Administered Orally to Subjects With Advanced Solid Tumors and Hematologic Malignancies

NCT01353625 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01353625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01353625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Multicenter, Open Label, Dosefinding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual Dna-pk and Tor Kinase Inhibitor, Cc-115, Administered Orally to Subjects With Advanced Solid Tumors and Hematologic Malignancies
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
April 25, 2011
Completion date
March 12, 2021
Enrollment
118 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, ewing's osteosarcoma, glioblastoma multiforme, neoplasm metastasis, prostate cancer, squamous cell carcinoma of head and neck